Hyubika HCT Tablet 5/40/12.5 mg

Adult dose

This medication should be taken once daily with one tablet with or without food. It is recommended to take it at the same time each day (e.g., in the morning) if possible. The recommended dosage varies based on the content of amlodipine/olmesartan medoxomil/hydrochlorothiazide, with a maximum dosage of 10/40/25 mg. Dosage adjustments should be made considering the patient’s blood pressure response, with intervals of more than 2 weeks between adjustments. Recommendations for dosage adjustments should also consider renal impairment, liver impairment, and elderly patients.

Child dose

Safety and efficacy in pediatric patients under 18 years of age have not been established, so the use of this medication is not recommended.

This medication can cause serious harm to the fetus during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with allergies to this drug or its ingredients, those with certain heart, kidney, or liver diseases, pregnant or nursing women, and patients with certain electrolyte imbalances. Patients with low blood volume or low salt may experience hypotensive symptoms when starting this medication, requiring careful monitoring and appropriate action if necessary. Patients with impaired kidney function, kidney transplant recipients, patients with renovascular hypertension, or those with liver function impairment require cautious observation and attention when using this medication. Because this drug has a strong blood pressure-lowering effect, elderly individuals or those with cardiovascular diseases should take extra care, as dizziness or lightheadedness may occur, and they should avoid dangerous machinery or driving. This medication may interact with various drugs, so it is important to consult with a physician or pharmacist if taking other medications. Regular blood tests to monitor electrolytes and kidney function are important during treatment with this medication. Nursing mothers are advised to avoid using this medication; if it is unavoidable, breastfeeding should be discontinued or the medication should be stopped. The safety and efficacy of this drug in children under 18 years of age have not been established, so its use is not recommended. In case of overdose, symptoms such as hypotension and palpitations may occur, and immediate medical attention should be sought for appropriate treatment. This medication should be stored away from direct sunlight and moisture, in a tightly sealed container, and should not be transferred to another container.

Serious side effects

Hives, severe swelling, chest tightness, difficulty breathing, cold sweats, pallor, severe allergic reactions, severe rash with fever, blisters, peeling skin, oral/eye mucosal pain, severe skin adverse reactions, shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities accompanied by cough and fever, breathing problems, yellowing of the skin or eyes (jaundice), extreme drowsiness, liver abnormalities (jaundice), sudden and severe reactions

Mild side effects

• Peripheral edema
• headache
• dizziness
• upper respiratory infection
• nasopharyngitis
• urinary tract infection
• sialadenitis
• leukopenia
• thrombocytopenia
• bone marrow suppression

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This helps to maintain the drug's efficacy.

Appearance

Light yellow round film-coated tablet

Package unit

30 tablets/PTP [(10 tablets/Alu-Alu × 3)]